CHEMOMAB THERAPEUTICS LTD (CMMB)

US16385C1045 - ADR

0.67  -0.03 (-4.29%)

Fundamental Rating

2

Taking everything into account, CMMB scores 2 out of 10 in our fundamental rating. CMMB was compared to 588 industry peers in the Biotechnology industry. CMMB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CMMB has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CMMB has reported negative net income.
In the past year CMMB has reported a negative cash flow from operations.
CMMB had negative earnings in each of the past 5 years.
CMMB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CMMB's Return On Assets of -109.33% is on the low side compared to the rest of the industry. CMMB is outperformed by 80.85% of its industry peers.
The Return On Equity of CMMB (-142.50%) is worse than 64.27% of its industry peers.
Industry RankSector Rank
ROA -109.33%
ROE -142.5%
ROIC N/A
ROA(3y)-64.32%
ROA(5y)N/A
ROE(3y)-79.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CMMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for CMMB has been increased compared to 1 year ago.
There is no outstanding debt for CMMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

There is no outstanding debt for CMMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 4.32 indicates that CMMB has no problem at all paying its short term obligations.
CMMB has a Current ratio (4.32) which is comparable to the rest of the industry.
CMMB has a Quick Ratio of 4.32. This indicates that CMMB is financially healthy and has no problem in meeting its short term obligations.
CMMB's Quick ratio of 4.32 is in line compared to the rest of the industry. CMMB outperforms 49.40% of its industry peers.
Industry RankSector Rank
Current Ratio 4.32
Quick Ratio 4.32

More info and screens

1

3. Growth

3.1 Past

CMMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.29%, which is quite impressive.
EPS 1Y (TTM)64.29%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q97.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 8.45% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25%
EPS Next 2Y8.01%
EPS Next 3Y10.06%
EPS Next 5Y8.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CMMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CMMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.01%
EPS Next 3Y10.06%

More info and screens

0

5. Dividend

5.1 Amount

CMMB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (4/19/2024, 12:50:06 PM)

0.67

-0.03 (-4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.13M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.33%
ROE -142.5%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.32
Quick Ratio 4.32
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)64.29%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y